**7. Conclusions**

HoFH is a rare disease that is underdiagnosed and undertreated and is associated with substantial morbidity and mortality. Early diagnosis and aggressive therapy are the corner‐ stones of the management of HoFH. Until recently, therapeutic options were limited and insufficient to get patients to their treatment goals. The availability of novel pharmacologic agents provides clinicians with additional treatment options in this difficult‐to‐treat popula‐ tion. **Figure 3** summarizes the suggested treatment algorithm of the EAS for patients with HoFH [10].

This algorithm highlights the novel treatment options that will allow greater reductions in lipid levels in HoFH patients and let them achieve their target goals. It is hoped and expected that these expanded options will ultimately translate into improvements in clinical outcomes including a decrease in CV events and CVD‐related mortality.

**Figure 3.** European Atherosclerosis Society treatment algorithm for the management of HoFH. Modified from Cuchel et al. 2014 [10].
